Pharmacokinetics of Citalopram in Patients With Short Bowel Syndrome
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This prospective study will determine the pharmacokinetic parameters of citalopram in 12 adult patients with short bowel syndrome. While data on the prevalence of depression in patients with short bowel syndrome is sparse, the investigators' experience is that these patients have a high incidence of depression and should benefit from a psychopharmacological intervention.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
19 Years to 65 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Subjects must be between the ages 19-65 years.
Subjects must have less than 200cm of functional small intestine.
Subjects must be at least one month post bowel resection.
Subjects less than 19 years or more than 65 years of age.
Pregnant or breastfeeding women.
Known hypersensitivity to citalopram or other SSRIs.
Diagnosis of depression using MINI (Mini International Neuropsychiatric Interview).
Ongoing antidepressant therapy.
Evidence of cirrhosis (Child-Pugh stages B or C) or evidence of significant liver impairment defined as liver enzymes elevations greater that 2.5 times the upper limit of normal.